Structure Therapeutics Inc. (NASDAQ:GPCR) Position Increased by Federated Hermes Inc.

Federated Hermes Inc. grew its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 104.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,267,206 shares of the company’s stock after purchasing an additional 1,157,006 shares during the period. Federated Hermes Inc.’s holdings in Structure Therapeutics were worth $92,411,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in GPCR. FMR LLC acquired a new position in shares of Structure Therapeutics in the 1st quarter valued at about $29,724,000. Wellington Management Group LLP acquired a new position in Structure Therapeutics in the first quarter worth approximately $2,377,000. Franklin Resources Inc. acquired a new position in Structure Therapeutics in the first quarter worth approximately $7,732,000. Prudential Financial Inc. acquired a new position in Structure Therapeutics in the first quarter worth approximately $999,000. Finally, BlackRock Inc. acquired a new position in Structure Therapeutics in the first quarter worth approximately $9,516,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on GPCR. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Thursday. Lifesci Capital restated an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $85.71.

Structure Therapeutics Trading Down 2.4 %

Shares of GPCR stock opened at $36.18 on Friday. Structure Therapeutics Inc. has a 12 month low of $21.79 and a 12 month high of $75.02. The business’s 50 day moving average is $40.81 and its two-hundred day moving average is $48.61.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. As a group, research analysts forecast that Structure Therapeutics Inc. will post -0.98 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.